Quantification of scyllo-inositol, a neurometabolite in Progressive Supranuclear Palsy


  • Biochemical profiling of the supplementary motor area (SMA) shows decreased levels of scyllo-inositol (Scyllo) in patients with Progressive Supranuclear Palsy (PSP) by using in vivo proton magnetic resonance spectroscopy (1H-MRS).

Why this matters

    Scyllo may protect against formation of toxic fibrils of amyloid-beta fragments as well as deposition of tau oligomers and hence can be a potential candidate for disease-modifying therapy for PSP.